Cardiovascular Pharmacology of Estradiol Metabolites

Journal of Pharmacology and Experimental Therapeutics

Volumn 308, Issue 2, 2004, Pages 403-409

  Dubey, Raghvendra K ^a,b   Tofovic, Stevan P ^b   Jackson, Edwin K ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL ESTRADIOL; CATECHOL ESTROGEN; CYTOCHROME P450; ESTRADIOL; ESTRADIOL 3 METHYL ETHER; ESTRADIOL DERIVATIVE; ESTROGEN RECEPTOR; SCLEROPROTEIN; UNCLASSIFIED DRUG;

ANIMAL; BLOOD VESSEL; CARDIOVASCULAR SYSTEM; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CYTOLOGY; ESTROGEN METABOLISM; FEMALE; FIBROBLAST; HEART MUSCLE; HEART PROTECTION; HUMAN; KIDNEY; MESANGIUM; METABOLISM; MOUSE; MOUSE MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RECEPTOR BINDING; REVIEW; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; ENDOTHELIUM, VASCULAR; ESTRADIOL; ESTROGENS, CATECHOL; FEMALE; FIBROBLASTS; GLOMERULAR MESANGIUM; HUMANS; MICE; MICE, KNOCKOUT; MYOCARDIUM;

EID: 1642539022     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.058057     Document Type: Review

References (40)

1. Bakir S, Mori T, Durand J, Chen YF, Thompson YF, and Oparil S (2000) Estrogen-induced vasoprotection is estrogen receptor dependent: evidence from balloon-injured rat carotid artery model. Circulation 101:2342-2344.
2. Barchiesi F, Jackson EK, Gillespie DG, Zacharia LC, Fingerle J, and Dubey RK (2002) Methoxyestradiols mediate estradiol-induced antimitogenesis in human aortic SMCs. Hypertension 39:874-879.
3. D'Amato RJ, Lin CM, Flynn E, Folkman J, and Hamel E (1994) 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA 91:3964-3968.
4. Dubey RK, Gillespie DG, Jackson EK, and Keller PJ (1998) β-estradiol, its metabolites, and progesterone inhibit cardiac fibroblast growth. Hypertension 31:522-528.
5. Dubey RK, Gillespie DG, Keller PJ, Imthurn B, Zacharia LC, and Jackson EK (2002a) Role of methoxyestradiols in the growth inhibitory effects of estradiol on human glomerular mesangial cells. Hypertension 39:418-424.
6. Dubey RK, Gillespie DG, Zacharia LC, Barchiesi F, Imthurn B, and Jackson EK (2003a) CYP450- and COMT-derived estradiol metabolites inhibit activity of human coronary artery SMCs. Hypertension 41:807-813.
7. Dubey RK, Gillespie DG, Zacharia LC, Rosselli M, Imthurn B, and Jackson EK (2002b) Methoxyestradiols mediate the antimitogenic effects of locally applied estradiol on cardiac fibroblast growth. Hypertension 39:412-417.
8. Dubey RK, Gillespie DG, Zacharia LC, Rosselli M, Korzekwa KR, Fingerle J, and Jackson EK (2000a) Methoxyestradiols mediate the antimitogenic effects of estradiol on vascular smooth muscle cells via estrogen receptor-independent mechanisms. Biochem Biophys Res Commun 278:27-33.
9. Dubey RK and Jackson EK (2001a) Estrogen-induced cardiorenal protection: potential cellular, biochemical and molecular mechanisms. Am J Physiol Renal Physiol 280:F365-F366.
10. Dubey RK and Jackson EK (2001b) Cardiovascular protective effects of 17β-estradiol metabolites. J Appl Physiol 91:1868-1883.
11. Dubey RK, Jackson EK, Gillespie DG, Zacharia LC, Imthurn B, and Keller PJ (2000b) Clinically used estrogens differentially inhibit human aortic smooth muscle cell growth and mitogen-activated protein kinase activity. Arterioscler Thromb Vasc Biol 20:964-972.
12. Dubey RK, Jackson EK, Keller PJ, Imthurn B, and Rosselli M (2001) Estradiol metabolites inhibit endothelin synthesis by an estrogen receptor-independent mechanism. Hypertension 37:640-644.
13. Dubey RK, Jackson EK, Rupprecht HD, and Sterzel RB (1997) Factors controlling growth and matrix production in vascular smooth muscle and glomerular mesangial cells. Curr Opin Nephrol Hypertension 6:88-105.
14. Dubey RK, Tyurina YY, Tyurin VA, Gillespie DG, Branch RA, Jackson EK, and Kagan VE (1999) Estrogen and tamoxifen metabolites protect smooth muscle cell membrane phospholipids against peroxidation and inhibit cell growth. Circ Res 84:229-239.
15. Dubey RK, Zacharia LC, Gillespie DG, Imthurn B, and Jackson EK (2003b) Catecholamines block the antimitogenic effect of estradiol on human glomerular mesangial cells. Hypertension 42:349-355.
16. Dunn JF, Merriam GR, Eil C, Kono S, Loriaux DL, and Nisula BC (1980) Testosterone-estradiol binding globulin binds to 2-methoxyestradiol with greater affinity than to testosterone. J Clin Endocrinol Metab 51:404-406.
17. Finking G, Lenz C, Schochat T, and Hanke H (2002) Reduction of post injury neointima formation due to 17beta-estradiol and phytoestrogen treatment is not influenced by the pure synthetic estrogen receptor antagonist ICI 182, 780. BMC Cardiovasc Disord 2:13 (Epub).
18. Fotsis T, Zhang Y, Pepper MS, Adlerereutz H, Montesano R, Nawroth PP, and Schweigerer L (1994) The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumor growth. Nature (Lond) 368:237-239.
19. Harada N, Sasano H, Murakami H, Ohkuma T, Nagura H, and Takagi Y (1999) Localized expression of aromatase in human vascular tissues. Circ Res 84:1285-1291.
20. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, and Vittinghoff E (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA (J Am Med Assoc) 280:605-613
21. Iafrati MD, Karas RH, Aronovitz M, Kim S, Sullivan TR Jr, Lubahn DB, O'Donnell TF, Korach KS, and Mendelsohn ME (1997) Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice. Nat Med 3:545-548.
22. Karas RH, Hodgin JB, Kwoun M, Krege JH, Aronovitz M, Mackey W, Gustafsson JA, Korach KS, Smithies O, and Mendelsohn ME (1999) Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc Natl Acad Sci USA 96:15133-15136.
23. Karas RH, Schulten H, Pare G, Aronovitz MJ, Ohlsson C, Gustafsson JA, and Mendelsohn ME (2001) Effects of estrogen on the vascular injury response in estrogen receptor alpha, beta (double) knockout mice. Circ Res 89:534-539.
24. Lee AJ, Cai MX, Thomas PE, Conney AH, and Zhu BT (2003) Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome P450 isoforms. Endocrinology 144:3382-3398.
25. Lippert C, Seeger H, Mueck AO, and Lippert TH (2000) The effects of A-ring and D-ring metabolites of estradiol on the proliferation of vascular endothelial cells. Life Sci 67:1653-1658.
26. Liu D and Bachmann KA (1998) An investigation of the relationship between estrogen, estrogen metabolites and blood cholestrol levels in ovariectomized rats. J Pharmacol Exp Ther 286:561-568.
27. Männistö PT and Kaakkola S (1999) Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51:593-628.
28. Oparil S, Levine RL, Chen SJ, Durand J, and Chen YF (1997) Sexually dimorphic response of the balloon-injured rat carotid artery to hormone treatment. Circulation 95:1301-1307.
29. Park BK (2000) Cytochrome P450 enzymes in the heart. The Lancet 355:945-946.
30. Rosenfeld CR and Jackson GM (1982) Induction and inhibition of uterine vasodilation by catechol estrogen in oophorectomized, nonpregnant eves. Endocrinology 110:1333-1339.
31. Sattler M, Quinnan LR, Pride YB, Gramlich JL, Chu SC, Even GC, Kraeft S-K, Chen LB, and Salgia R (2003) 2-Methoxyestradiol alters cell motility, migration and adhesion. Blood 102:289-296.
32. Seeger H, Mueck AO, and Lippert TH (1997) Effect of estradiol metabolites on the susceptibility of low density lipoprotein to oxidation. Life Sci 61:865-868.
33. Seeger H, Mueck AO, and Lippert TH (1999) Effect of estradiol metabolites on prostacyclin synthesis in human endothelial cell cultures. Life Sci 65:PL167-PL170.
34. Tofovic SP, Dubey RK, and Jackson EK (2001) 2-Hydroxyestradiol attenuates the development of obesity, the metabolic syndrome and vascular and renal dysfunction in obese ZSF1 rats. J Pharmacol Exp Ther 299:973-977.
35. Tofovic SP, Dubey R, Salah EM, and Jackson EK (2002) 2-Hydroxyestradiol attenuates renal disease in chronic puromycin aminonucleoside nephropathy. J Am Soc Nephrol 13:2737-2747.
36. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA (J Am Med Assoc) 288:321-333.
37. Yue TL, Wang X, Louden CS, Gupta S, Pillarisetti K, Gu JL, Hart TK, Lysko PG, and Feuerstein GZ (1997) 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol Pharmacol 51:951-962.
38. Zacharia LC, Jackson EK, Gillespie DG, and Dubey RK (2001) Increased 2-methoxyestradiol production in human coronary versus aortic vascular cells. Hypertension 37:658-662.
39. Zacharia LC, Gogos JA, Karayiorgou M, Jackson EK, Gillespie DG, Barchiesi F, and Dubey RK (2003) Methoxyestradiols mediate the antimitogenic effects of 17β-estradiol. Direct evidence from catechol-O-methyltransferase-knockout mice. Circulation: published online before print December 8, 2003, 10.1161/01. CIR.0000106900.66354.30.
40. Zhu BT and Conney AH (1998) Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19:1-37.